An RNA nanoparticle Vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Chahal, Jasdave S ^a,b   Fang, Tao ^a   Woodham, Andrew W ^a   Khan, Omar F ^b   Ling, Jingjing ^a   Anderson, Daniel G ^b   Ploegh, Hidde L ^a,c  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRIMER; EPITOPE; IMMUNOGLOBULIN G; NANOPARTICLE; VIRUS ANTIBODY; VIRUS RNA; VIRUS VACCINE;

ANIMAL; BLOOD; C57BL MOUSE; CD8+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; ISOLATION AND PURIFICATION; ZIKA FEVER; ZIKA VIRUS;

ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DENDRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; IMMUNOGLOBULIN G; MICE, INBRED C57BL; NANOPARTICLES; RNA, VIRAL; VIRAL VACCINES; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85020867312     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-00193-w     Document Type: Article

References (47)

1. Cao-Lormeau, V.-M. et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a casecontrol study. The Lancet 387, 1531-1539, doi:10.1016/S0140-6736 (16) 00562-6 (2016).
2. Oehler, E. et al. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveill 19, doi:20720 (2014).
3. Brasil, P. et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro - Preliminary Report. New England Journal of Medicine 375, 2321-2334, doi:10.1056/NEJMoa1602412 (2016).
4. Sarno, M. et al. Zika Virus Infection and Stillbirths: A Case of Hydrops Fetalis, Hydranencephaly and Fetal Demise. PLoS Negl Trop Dis 10, e0004517, doi:10.1371/journal.pntd.0004517 (2016).
5. CDC. Zika virus disease in the United States, 2015-2016, http://www.cdc.gov/zika/geo/united-states.html (2016).
6. CDC. Advice for people living in or traveling to Wynwood, a neighborhood in Miami, FL, http://www.cdc.gov/zika/intheus/floridaupdate.html (2016).
7. Health, C. o. N. Y. Zika Virus: Travel Alerts, https://www1.nyc.gov/site/doh/health/health-topics/zika-virus.page (2016).
8. Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474-478, doi:10.1038/nature18952 (2016).
9. National Institute of Allergy and Infectious Diseases. Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults, https://clinicaltrials.gov/ct2/show/NCT02840487 (2016).
10. Kwilas, S. et al. A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates. Curr Gene Ther 14, 200-210, doi: CGT-EPUB-60639 (2014).
11. Faye, O. et al. Molecular evolution of Zika virus during its emergence in the 20th century. PLoS Negl Trop Dis 8, e2636, doi:10.1371/journal.pntd.0002636 (2014).
12. Zanluca, C. et al. First report of auto chthonous transmission of Z ika vir us in Brazil. Mem Inst Oswaldo Cruz 110, 569-572, doi:10.1590/0074-02760150192 (2015).
13. Lanciotti, R. S., Lambert, A. J., Holodniy, M., Saavedra, S. & Signor Ldel, C. Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerg Infect Dis 22, 933-935, doi:10.3201/eid2205.160065 (2016).
14. Haddow, A. D. et al. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl Trop Dis 6, e1477, doi:10.1371/journal.pntd.0001477 (2012).
15. Fagbami, A. H. Zika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo State. J Hyg (Lond) 83, 213-219 (1979).
16. Kirya, B. G. & Okia, N. O. A yellow fever epizootic in Zika Forest, Uganda, during 1972: Part 2: Monkey serology. Trans R Soc Trop Med Hyg 71, 300-303 (1977).
17. Simpson, D. I. Zika Virus Infection in Man. Trans R Soc Trop Med Hyg 58, 335-338 (1964).
18. Mettler, N. E., Clarke, D. H. & Casals, J. Hemagglutination inhibition with arboviruses: relationship between titers and source of erythrocytes. Appl Microbiol 22, 377-379 (1971).
19. Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol 17, 1102-1108, doi:10.1038/ni.3515 (2016).
20. Lazear, H. M. et al. A Mouse Model of Zika Virus Pathogenesis. Cell Host Microbe 19, 720-730, doi:10.1016/j.chom.2016.03.010 (2016).
21. Rossi, S. L. et al. Characterization of a Novel Murine Model to Study Zika Virus. Am J Trop Med Hyg 94, 1362-1369, doi:10.4269/ajtmh.16-0111 (2016).
22. Miner, J. J. et al. Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise. Cell 165, 1081-1091, doi:10.1016/j.cell.2016.05.008 (2016).
23. Rodriguez-Morales, A. J. et al. Mapping Zika virus infection using geographical information systems in Tolima, Colombia, 2015-2016. F1000Res 5, 568, doi:10.12688/f1000research.8436.1 (2016).
24. Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature. doi:10.1038/nature18952 (2016).
25. + T cells complement antibodies in protecting against yellow fever virus. J Immunol 194, 1141-1153, doi:10.4049/jimmunol.1402605 (2015).
26. Mathew, A., Townsley, E. & Ennis, F. A. Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections. Future Microbiol 9, 411-425, doi:10.2217/fmb.13.171 (2014).
27. + T cells in control of West Nile virus infection. J Virol 78, 8312-8321, doi:10.1128/JVI.78.15.8312-8321.2004 (2004).
28. Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci USA 113, E4133-4142, doi:10.1073/pnas.1600299113 (2016).
29. Enfissi, A., Codrington, J., Roosblad, J., Kazanji, M. & Rousset, D. Zika virus genome from the Americas. Lancet 387, 227-228, doi:10.1016/S0140-6736 (16) 00003-9 (2016).
30. Froshauer, S., Kartenbeck, J. & Helenius, A. Alphavirus Rna Replicase Is Located on the Cytoplasmic Surface of Endosomes and Lysosomes. J Cell Biol 107, 2075-2086, doi:10.1083/jcb.107.6.2075 (1988).
31. Li, M. L. & Stollar, V. Alphaviruses and apoptosis. International reviews of immunology 23, 7-24 (2004).
32. Chang, G. J., Davis, B. S., Hunt, A. R., Holmes, D. A. & Kuno, G. Flavivirus DNA vaccines: current status and potential. Annals of the New York Academy of Sciences 951, 272-285 (2001).
33. Lee, J. E. & Saphire, E. O. Ebolavirus glycoprotein structure and mechanism of entry. Future Virol 4, 621-635, doi:10.2217/fvl.09.56 (2009).
34. Rey, F. A., Heinz, F. X., Mandl, C., Kunz, C. & Harrison, S. C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375, 291-298, doi:10.1038/375291a0 (1995).
35. Modis, Y., Ogata, S., Clements, D. & Harrison, S. C. Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319, doi:10.1038/nature02165 (2004).
36. Nybakken, G. E. et al. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437, 764-769, doi: nature03956 (2005).
37. Nielsen, M. et al. Reliable prediction of T-cell epitop es using neural networks w ith novel sequence representations. Protein Sci 12, 1007-1017, doi:10.1110/ps.0239403 (2003).
38. Lundegaard, C. et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36, W509-512, doi:10.1093/nar/gkn202 (2008).
39. Simon, M. D. et al. Rapid flow-based peptide synthesis. Chembiochem 15, 713-720, doi:10.1002/cbic.201300796 (2014).
40. Schumacher, T. N. et al. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 62, 563-567. doi:0092-8674 (90) 90020-F (1990).
41. Feltkamp, M. C. et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23, 2242-2249, doi:10.1002/eji.1830230929 (1993).
42. Lipford, G. B., Hoffman, M., Wagner, H. & Heeg, K. Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol 150, 1212-1222 (1993).
43. Kast, W. M. et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA 88, 2283-2287 (1991).
44. Al-Ahdal, M. N., Nakamura, I. & Flanagan, T. D. Cytotoxic T-lymphocyte reactivity with individual Sendai virus glycoproteins. J Virol 54, 53-57 (1985).
45. Deres, K. et al. Preferred size of peptides that bind to H-2 Kb is sequence dependent. Eur J Immunol 22, 1603-1608, doi:10.1002/eji.1830220638 (1992).
46. de Waal, L. P., Kast, W. M., Melvold, R. W. & Melief, C. J. Regulation of the cytotoxic T lymphocyte response against Sendai virus analyzed with H-2 mutants. J Immunol 130, 1090-1096 (1983).
47. Rudolph, M. G. et al. The crystal structures of K (bm1) and K (bm8) reveal that subtle changes in the peptide environment impact thermostability and alloreactivity. Immunity 14, 231-242, doi: S1074-7613 (01) 00105-4 (2001).